How has the management of medullary thyroid carcinoma changed with the advent of 18F-FDG and non- 18F-FDG PET radiopharmaceuticals

Ka Kit Wong, Amanda M. Laird, Amir Moubayed, Sotirios Chondrogiannis, Maria Cristina Marzola, Laura Evangelista, Milton D. Gross, Domenico Rubello

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Medullary thyroid cancer (MTC) arises from parafollicular C cells and is an elusive tumor to image. It occurs as a sporadic neoplasm in 70-80% of cases and is hereditary in 20-30% because of germline mutations of the rearranged during transfection proto-oncogene. Successful disease management relies on accurate staging. Tumor secretory biomarkers are highly sensitive to a disease; however, despite a wide variety of radiopharmaceuticals for molecular imaging that take advantage of hybrid SPECT/CT and PET/CT fusion imaging, imaging of MTC is still problematic. After initial surgical resection, the limited sensitivity of localization of small locoregional disease and the inability to detect early liver metastases hamper the success of later surgical approaches. 18F-fluorodeoxyglucose PET has been used to detect MTC recurrences with modest success and may be best suited for only a small subset of more biologically aggressive MTCs. Recent developments in PET imaging with novel radiopharmaceuticals targeting specific cellular processes of MTC offer increased sensitivity for identifying recurrence, assessing prognosis, and guiding selection of optimal therapies.

Original languageEnglish
Pages (from-to)679-688
Number of pages10
JournalNuclear Medicine Communications
Volume33
Issue number7
DOIs
Publication statusPublished - Jul 2012

Fingerprint

Radiopharmaceuticals
Fluorodeoxyglucose F18
Recurrence
Molecular Imaging
Proto-Oncogenes
Germ-Line Mutation
Tumor Biomarkers
Disease Management
Transfection
Neoplasms
Neoplasm Metastasis
Medullary Thyroid cancer
Liver
Therapeutics

Keywords

  • F- fluorodeoxyglucose
  • F-fluorodihydroxyphenylalanine
  • conventional imaging
  • medullary thyroid cancer
  • PET
  • restaging
  • staging

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

How has the management of medullary thyroid carcinoma changed with the advent of 18F-FDG and non- 18F-FDG PET radiopharmaceuticals. / Wong, Ka Kit; Laird, Amanda M.; Moubayed, Amir; Chondrogiannis, Sotirios; Marzola, Maria Cristina; Evangelista, Laura; Gross, Milton D.; Rubello, Domenico.

In: Nuclear Medicine Communications, Vol. 33, No. 7, 07.2012, p. 679-688.

Research output: Contribution to journalArticle

Wong, Ka Kit ; Laird, Amanda M. ; Moubayed, Amir ; Chondrogiannis, Sotirios ; Marzola, Maria Cristina ; Evangelista, Laura ; Gross, Milton D. ; Rubello, Domenico. / How has the management of medullary thyroid carcinoma changed with the advent of 18F-FDG and non- 18F-FDG PET radiopharmaceuticals. In: Nuclear Medicine Communications. 2012 ; Vol. 33, No. 7. pp. 679-688.
@article{5e2074ac54a24a57b62b32bdea94fef7,
title = "How has the management of medullary thyroid carcinoma changed with the advent of 18F-FDG and non- 18F-FDG PET radiopharmaceuticals",
abstract = "Medullary thyroid cancer (MTC) arises from parafollicular C cells and is an elusive tumor to image. It occurs as a sporadic neoplasm in 70-80{\%} of cases and is hereditary in 20-30{\%} because of germline mutations of the rearranged during transfection proto-oncogene. Successful disease management relies on accurate staging. Tumor secretory biomarkers are highly sensitive to a disease; however, despite a wide variety of radiopharmaceuticals for molecular imaging that take advantage of hybrid SPECT/CT and PET/CT fusion imaging, imaging of MTC is still problematic. After initial surgical resection, the limited sensitivity of localization of small locoregional disease and the inability to detect early liver metastases hamper the success of later surgical approaches. 18F-fluorodeoxyglucose PET has been used to detect MTC recurrences with modest success and may be best suited for only a small subset of more biologically aggressive MTCs. Recent developments in PET imaging with novel radiopharmaceuticals targeting specific cellular processes of MTC offer increased sensitivity for identifying recurrence, assessing prognosis, and guiding selection of optimal therapies.",
keywords = "F- fluorodeoxyglucose, F-fluorodihydroxyphenylalanine, conventional imaging, medullary thyroid cancer, PET, restaging, staging",
author = "Wong, {Ka Kit} and Laird, {Amanda M.} and Amir Moubayed and Sotirios Chondrogiannis and Marzola, {Maria Cristina} and Laura Evangelista and Gross, {Milton D.} and Domenico Rubello",
year = "2012",
month = "7",
doi = "10.1097/MNM.0b013e3283529bf7",
language = "English",
volume = "33",
pages = "679--688",
journal = "Nuclear Medicine Communications",
issn = "0143-3636",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

TY - JOUR

T1 - How has the management of medullary thyroid carcinoma changed with the advent of 18F-FDG and non- 18F-FDG PET radiopharmaceuticals

AU - Wong, Ka Kit

AU - Laird, Amanda M.

AU - Moubayed, Amir

AU - Chondrogiannis, Sotirios

AU - Marzola, Maria Cristina

AU - Evangelista, Laura

AU - Gross, Milton D.

AU - Rubello, Domenico

PY - 2012/7

Y1 - 2012/7

N2 - Medullary thyroid cancer (MTC) arises from parafollicular C cells and is an elusive tumor to image. It occurs as a sporadic neoplasm in 70-80% of cases and is hereditary in 20-30% because of germline mutations of the rearranged during transfection proto-oncogene. Successful disease management relies on accurate staging. Tumor secretory biomarkers are highly sensitive to a disease; however, despite a wide variety of radiopharmaceuticals for molecular imaging that take advantage of hybrid SPECT/CT and PET/CT fusion imaging, imaging of MTC is still problematic. After initial surgical resection, the limited sensitivity of localization of small locoregional disease and the inability to detect early liver metastases hamper the success of later surgical approaches. 18F-fluorodeoxyglucose PET has been used to detect MTC recurrences with modest success and may be best suited for only a small subset of more biologically aggressive MTCs. Recent developments in PET imaging with novel radiopharmaceuticals targeting specific cellular processes of MTC offer increased sensitivity for identifying recurrence, assessing prognosis, and guiding selection of optimal therapies.

AB - Medullary thyroid cancer (MTC) arises from parafollicular C cells and is an elusive tumor to image. It occurs as a sporadic neoplasm in 70-80% of cases and is hereditary in 20-30% because of germline mutations of the rearranged during transfection proto-oncogene. Successful disease management relies on accurate staging. Tumor secretory biomarkers are highly sensitive to a disease; however, despite a wide variety of radiopharmaceuticals for molecular imaging that take advantage of hybrid SPECT/CT and PET/CT fusion imaging, imaging of MTC is still problematic. After initial surgical resection, the limited sensitivity of localization of small locoregional disease and the inability to detect early liver metastases hamper the success of later surgical approaches. 18F-fluorodeoxyglucose PET has been used to detect MTC recurrences with modest success and may be best suited for only a small subset of more biologically aggressive MTCs. Recent developments in PET imaging with novel radiopharmaceuticals targeting specific cellular processes of MTC offer increased sensitivity for identifying recurrence, assessing prognosis, and guiding selection of optimal therapies.

KW - F- fluorodeoxyglucose

KW - F-fluorodihydroxyphenylalanine

KW - conventional imaging

KW - medullary thyroid cancer

KW - PET

KW - restaging

KW - staging

UR - http://www.scopus.com/inward/record.url?scp=84862238171&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862238171&partnerID=8YFLogxK

U2 - 10.1097/MNM.0b013e3283529bf7

DO - 10.1097/MNM.0b013e3283529bf7

M3 - Article

C2 - 22422100

AN - SCOPUS:84862238171

VL - 33

SP - 679

EP - 688

JO - Nuclear Medicine Communications

JF - Nuclear Medicine Communications

SN - 0143-3636

IS - 7

ER -